RESEARCH TRIANGLE PARK, N.C., May 24, 2016 /PRNewswire/ -- Don Van Dyke, COO of Cloud Pharmaceuticals Inc., a cloud-based drug design and development company, is being featured as a panelist at the 2016 BIO International Convention taking place June 6 through 9, 2016 in San Francisco, Calif. The session, titled "Digital Tools for Drug Discovery and Development: Leverage Moore's Law to Improve Therapeutics," is being held June 9, 2016, from 9:00 to 10:15 am in room West 3006. Van Dyke and fellow panelists will explore advances in computer modeling to reduce drug development cost and improve time to market.
"The computational design of drugs has faced stumbling blocks in the past but several things have come together to make it the most promising venue for drug discovery," says Van Dyke. "Cloud computing combined with the continued influence of Moore's Law has provided an unprecedented opportunity to apply inexpensive high-performance computing to drug discovery. This combination offers new techniques that can be combined to achieve success at a higher level – from molecule design through clinical trials. It allows us to harness the power of artificial intelligence (AI) to design molecules that can heal and save."
The application of cloud computing combined with AI technology enables computational chemistry processes and sophisticated molecular modeling to search virtual molecular space and design novel drugs that are well-qualified for development from the outset. This approach represents the digital disruption of drug design, enabling faster development at lower cost and a higher success rate with better targeting of hard-to-drug indications.
"The goal is to not only reduce cost and improve speed," Van Dyke adds. "It's about producing much-improved compounds that have a high probability of success at becoming safe, effective, and marketable drugs. This technology represents a tremendous step forward in computational drug design, with broad applications in drug discovery."
About Cloud Pharmaceuticals, Inc.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications. For information visit www.cloudpharmaceuticals.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
ProfNet: Ed Addison
SOURCE Cloud Pharmaceuticals, Inc.